A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Evaluate the Safety and Effectiveness of LUCEMYRA in the Treatment of Opioid Withdrawal During an Opioid Taper in Subjects With Chronic Non-Cancer Pain
Latest Information Update: 23 Oct 2024
At a glance
- Drugs Lofexidine (Primary)
- Indications Opioid-related disorders
- Focus Adverse reactions
- Acronyms TAPER
- Sponsors US WorldMeds
Most Recent Events
- 21 Oct 2024 Status changed from suspended to discontinued. (COVID pandemic and enrollment issues necessitating an adjustment to the study design.)
- 11 Mar 2022 Planned End Date changed from 1 Dec 2021 to 31 Oct 2022.
- 11 Mar 2022 Planned primary completion date changed from 1 Dec 2021 to 31 Oct 2022.